CGON (CG Oncology) Equity-to-Asset : 0.97 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CG Oncology's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $733.38 Mil. CG Oncology's Total Assets for the quarter that ended in Dec. 2024 was $754.80 Mil. Therefore, CG Oncology's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.97.

The historical rank and industry rank for CG Oncology's Equity-to-Asset or its related term are showing as below:

CGON' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.69 Med: 0.89 Max: 0.97
Current: 0.97

During the past 4 years, the highest Equity to Asset Ratio of CG Oncology was 0.97. The lowest was 0.69. And the median was 0.89.

CGON's Equity-to-Asset is ranked better than
98.47% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs CGON: 0.97

CG Oncology Equity-to-Asset Historical Data

The historical data trend for CG Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Equity-to-Asset Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Equity-to-Asset

0.69

0.85

0.93

0.97

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial					0.93	0.98	0.98	0.97	0.97

Competitive Comparison of CG Oncology's Equity-to-Asset

For the Biotechnology subindustry, CG Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CG Oncology's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

CG Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CG Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	733.377	/	754.797
	=	0.97

CG Oncology's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	733.377	/	754.797
	=	0.97

CG Oncology (NAS:CGON) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

CG Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of CG Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.